Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Sara Gulesserian"'
Autor:
Fernando Doñate, David R. Stover, Sher Karki, Hector Aviña, Lisa Do, Josh Snyder, Veronica Robles, Zhilan Zeng, Karen Morrison, Jimmy Ou, Sathish Kumar Ganesan, Sara Gulesserian, Hui Zhao
Fig. S1. Structure of AGS-16C3F; Figure S2. ENPP3 was not expressed in megakaryocytes; Figure S3. AGS-16C3F did not affect platelet activation; Figure S4. Maturing MKs did not express ENPP3; Figure S5. Fc blocker inhibited FcγRIIA pathway in tumor c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00342acdda45c0ff67ce6d7bb2934973
https://doi.org/10.1158/1535-7163.22509028
https://doi.org/10.1158/1535-7163.22509028
Autor:
Fernando Doñate, David R. Stover, Brian A. Mendelsohn, Michael Mattie, Zhilan Zeng, Melissa M. Williams, Mi Sook Chang, James Song, Sathish Kumar Ganesan, Maria Christina Malinao, Sara Gulesserian, Hui Zhao
Figure S1. Chemical structures of MMAF, MMAE and 13C5-MMAE. The asterisks indicate where Carbon-13 isotope has replaced Carbon-12; Figure S2. Expression of CD32 on mature neutrophils. Circulating neutrophils (AllCell) were incubated with anti-CD32 an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::660456dd4858e9bbebfdffd3e06f96c3
https://doi.org/10.1158/1535-7163.22508311
https://doi.org/10.1158/1535-7163.22508311
Autor:
Fernando Doñate, David R. Stover, Brian A. Mendelsohn, Roland Luethy, Sung-Ju Moon, Josh Snyder, Linnette Capo, René Hubert, Hector Aviña, Sher Karki, Pia Challita-Eid, Faisal Malik, Jeffrey Coleman, Karen Morrison, Peng Yang, Jimmy Ou, Jenny Nater, Zhilan Zeng, Sara Gulesserian, John Atkinson, Hui Zhao
AGS-16C3F is an antibody–drug conjugate (ADC) against ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) containing the mcMMAF linker-payload currently in development for treatment of metastatic renal cell carcinoma. AGS-16C3F and other ADC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15490f6d4322c9192d3919e4ad7ff9a9
https://doi.org/10.1158/0008-5472.c.6510380.v1
https://doi.org/10.1158/0008-5472.c.6510380.v1
Autor:
Fernando Doñate, David R. Stover, Brian A. Mendelsohn, Roland Luethy, Sung-Ju Moon, Josh Snyder, Linnette Capo, René Hubert, Hector Aviña, Sher Karki, Pia Challita-Eid, Faisal Malik, Jeffrey Coleman, Karen Morrison, Peng Yang, Jimmy Ou, Jenny Nater, Zhilan Zeng, Sara Gulesserian, John Atkinson, Hui Zhao
Supplemental tables 1-5: Table 1: Characteristics of peptide modified ADCs tested and IC50 in the HCEC and KU812 assays. Table 2: Characteristics. of PEG modified ADCs tested and data in the HCEC and KU812 assays. Table 3: Characteristics of mutated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b7610130a3c9e9e7370a263155dfda9
https://doi.org/10.1158/0008-5472.22419443
https://doi.org/10.1158/0008-5472.22419443
Autor:
Karen Morrison, Hector Aviña, Sathish Kumar Ganesan, Jimmy Ou, Veronica Robles, Josh Snyder, Zhilan Zeng, Hui Zhao, Sher Bahadur Karki, Fernando Donate, David R. Stover, Lisa Do, Sara Gulesserian
Publikováno v:
Molecular Cancer Therapeutics. 16:1877-1886
Thrombocytopenia is a common adverse event in cancer patients treated with antibody–drug conjugates (ADC), including AGS-16C3F, an ADC targeting ENPP3 (ectonucleotide pyrophosphatase/phosphodiesterase-3) and trastuzumab emtansine (T-DM1). This stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac7868f293260a94c5e6f60e2b8beb08
https://doi.org/10.1158/1535-7163.mct-16-0710
https://doi.org/10.1158/1535-7163.mct-16-0710
Autor:
Mi Sook Chang, Fernando Donate, Michael D. Mattie, Sara Gulesserian, Melissa M. Williams, Sathish Kumar Ganesan, Zhilan Zeng, Hui Zhao, David R. Stover, Brian A. Mendelsohn, Maria-Christina Malinao, James Song
Publikováno v:
Molecular Cancer Therapeutics. 16:1866-1876
Neutropenia is a common adverse event in cancer patients treated with antibody–drug conjugates (ADC) and we aimed to elucidate the potential mechanism of this toxicity. To investigate whether ADCs affect neutrophil production from bone marrow, an i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4baab18deca0572d367967394d221806
https://doi.org/10.1158/1535-7163.mct-17-0133
https://doi.org/10.1158/1535-7163.mct-17-0133
Autor:
Pia M. Challita-Eid, Karen Morrison, Sung-Ju Moon, Rene S. Hubert, Jenny Nater, Peng Yang, Faisal Malik, Josh Snyder, Roland Luethy, Hector Aviña, Jimmy Ou, Brian A. Mendelsohn, Linnette Capo, Sher Karki, Jeffrey O. Coleman, Zhilan Zeng, Hui Zhao, Fernando Donate, Sara Gulesserian, John P. Atkinson, David R. Stover
Publikováno v:
Cancer research. 78(8)
AGS-16C3F is an antibody–drug conjugate (ADC) against ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) containing the mcMMAF linker-payload currently in development for treatment of metastatic renal cell carcinoma. AGS-16C3F and other ADC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c949207f10c990a4dcf0537425c22bee
https://pubmed.ncbi.nlm.nih.gov/29382707
https://pubmed.ncbi.nlm.nih.gov/29382707
Autor:
Ranjana H. Advani, Kerry J. Savage, Hector Aviña, Hui Zhao, Ahmed Sawas, Karen Morrison, Leonard M. Reyno, Sher Karki, Jacqueline Lackey, Peng Yang, Owen A. O'Connor, Jasmine Zain, Raymond P. Perez, Fernando Donate, Sara Gulesserian
Publikováno v:
Cancer Research. 77:2709-2709
AGS67E is an antibody drug conjugate (ADC) against CD37 conjugated to monomethyl auristatin E (MMAE). CD37 is expressed on normal WBCs, but is also highly expressed in NHL, CLL and AML (Pereira et al., 2015). A phase I study is currently evaluating t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1b3b010e3ec1bfb632befb77e118120
https://doi.org/10.1158/1538-7445.am2017-2709
https://doi.org/10.1158/1538-7445.am2017-2709
Autor:
Zhilan Zeng, Hui Zhao, Sathish Kumar Ganesan, David R. Stover, Veronica Robles, Jimmy Ou, Sara Gulesserian, Josh Snyder, Fernando Donate
Publikováno v:
Cancer Research. 76:3853-3853
Thrombocytopenia and neutropenia are common adverse events in cancer patients treated with antibody-drug conjugates (ADCs). We used human hematopoietic stem cells (HSC) in vitro and various ADCs to investigate the potential mechanisms of thrombocytop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1efd9b162253ca04b7e727b47ea34ee
https://doi.org/10.1158/1538-7445.am2016-3853
https://doi.org/10.1158/1538-7445.am2016-3853